Though pediatric cardiomyopathy is rare in children, there is significant associated morbidity and mortality. Etiology varies from inborn errors of metabolism to familial genetic mutations and myocyte injury. Major classes include dilated, hypertrophic, restrictive, and non-compaction. Diagnosis generally involves a combination of clinical history and echocardiography. The use of cross-sectional imaging is gaining popularity. Management varies between subtype and may involve a combination of medical and surgical interventions depending on clinical status.
TowbinJALoweAMColanSD, et al.Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 2006;296(15):1867. 1876. doi:10.1001/jama.296.15.1867.
2.
CohenJAAlmodovarMC. Dilated cardiomyopathy in children: moving beyond traditional pharmacologic therapy. Curr Opin Cardiol. 2020;35(1):52-57. doi:10.1097/HCO.0000000000000692.
3.
LipshultzSELawYMAsante-KorangA, et al.Cardiomyopathy in children: classification and diagnosis: a scientific statement from the American heart association. Circulation. 2019;140(1):E9-E68. doi:10.1161/CIR.0000000000000682.
4.
JappAGGulatiACookSACowieMRPrasadSK. The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol. 2016;67(25):2996-3010. doi:10.1016/j.jacc.2016.03.590.
5.
KimSJ. Pediatric acute myocarditis: current approach to diagnosis and treatment. Korean Circ J. 2020;50(11):1023-1025. doi:10.4070/KCJ.2020.0389.
6.
IshiiRSteve FanCPMertensLManlhiotCFriedbergMK. Longitudinal prediction of transplant-free survival by echocardiography in pediatric dilated cardiomyopathy. Can J Cardiol. 2021;37(6):867-876. doi:10.1016/j.cjca.2020.12.010.
7.
PophalSGSigfussonGBoothKL, et al.Complications of endomyocardial biopsy in children. J Am Coll Cardiol. 1999;34(7):2105-2110.
8.
ElbadawiAElgendyIYHaLD, et al.National trends and outcomes of endomyocardial biopsy for patients with myocarditis: from the national inpatient sample database. J Card Fail. 2018;24(5):337-341. doi:10.1016/j.cardfail.2018.03.013.
9.
QuiatDWitkowskiLZoukHDalyKPRobertsAE. Retrospective analysis of clinical genetic testing in pediatric primary dilated cardiomyopathy: testing outcomes and the effects of variant reclassification. J Am Heart Assoc. 2020;9(11):e016195. doi:10.1161/JAHA.120.016195.
10.
AhmedHVanderPluymC. Medical management of pediatric heart failure. Cardiovasc Diagn Ther. 2021;11(1):323-335. doi:10.21037/cdt-20-358.
11.
ButtsRJBoyleGJDeshpandeSR, et al.Characteristics of clinically diagnosed pediatric myocarditis in a contemporary multi-center cohort. Pediatr Cardiol. 2017;38(6):1175-1182. doi:10.1007/s00246-017-1638-1.
12.
DruckerNAColanSDLewisAB, et al.Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation. 1994;89(1):252-257. https://ahajournals.org
13.
PonikowskiPVoorsAAAnkerSD, et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi:10.1093/eurheartj/ehw128.
14.
HarmonWGSleeperLACunibertiL, et al.Treating children with idiopathic dilated cardiomyopathy (from the pediatric cardiomyopathy registry). Am J Cardiol. 2009;104(2):281-286. doi:10.1016/j.amjcard.2009.03.033.
15.
MaronBJTowbinJAThieneG, et al.Contemporary definitions and classification of the cardiomyopathies: an American heart association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113(14):1807-1816. doi:10.1161/CIRCULATIONAHA.106.174287.
16.
ShaddyRCanterCHalnonN, et al.Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). Am Heart J. 2017;193:23-34. doi:10.1016/j.ahj.2017.07.006.
17.
NewlandDMLawYMAlbersEL, et al.Early clinical experience with dapagliflozin in children with heart failure. Pediatr Cardiol. 2023;44(1):146-152. doi:10.1007/s00246-022-02983-0.
18.
ThrushPTHoffmanTM. Pediatric heart transplantation-indications and outcomes in the current era. J Thorac Dis. 2014;6(8):1080-1096. doi:10.3978/j.issn.2072-1439.2014.06.16.
19.
DipchandAIRossanoJWEdwardsLB, et al.The registry of the international society for heart and lung transplantation: eighteenth official pediatric heart transplantation report - 2015; focus theme: early graft failure. J Heart Lung Transplant. 2015;34(10):1233-1243. doi:10.1016/j.healun.2015.08.002.
20.
AdachiIBurkiSFraserCD. Current status of pediatric ventricular assist device support. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2017;20:2-8. doi:10.1053/j.pcsu.2016.09.010.
21.
FraserCDJaquissRDRosenthalDN, et al.Prospective trial of a pediatric ventricular assist device. N Engl J Med. 2012;367:532-541. doi:10.1056/NEJMoa1014164.
22.
LortsAZafarFVanderpluymC, et al.Contemporary Berlin heart EXCOR outcomes in North America: report from the ACTION registry. J Heart Lung Transplant. 2020;39(4):S131.
23.
O’ConnorMJLortsADaviesRR, et al.Early experience with the HeartMate 3 continuous-flow ventricular assist device in pediatric patients and patients with congenital heart disease: a multicenter registry analysis. J Heart Lung Transplant. 2020;39(6):573-579. doi:10.1016/j.healun.2020.02.007.
24.
O’ConnorMJShezadMAhmedH, et al.Expanding use of the HeartMate 3 ventricular assist device in pediatric and adult patients within the advanced cardiac therapies improving outcomes network (ACTION). J Heart Lung Transplant. 2023;42(11):1546-1556. doi:10.1016/j.healun.2023.06.015.
25.
AdachiIPengDMHollanderSA, et al.Sixth annual pediatric interagency registry for mechanical circulatory support (pedimacs) report: the society of thoracic surgeons pedimacs annual report. Ann Thorac Surg. 2023;115:1098-1108. doi:10.1016/j.athoracsur.
26.
LortsASmythLGajarskiRJ, et al.The creation of a pediatric health care learning network: the ACTION quality improvement collaborative. Am Soc Artif Intern Organs J. 2020;66(4):441-446. doi:10.1097/MAT.0000000000001133.
27.
MotonagaKSDubinAM. Cardiac resynchronization therapy for pediatric patients with heart failure and congenital heart disease: a reappraisal of results. Circulation. 2014;129(18):1879-1891. doi:10.1161/CIRCULATIONAHA.113.001383.
28.
EverittMDSleeperLALuM, et al.Recovery of echocardiographic function in children with idiopathic dilated cardiomyopathy: results from the pediatric cardiomyopathy registry. J Am Coll Cardiol. 2014;63(14):1405-1413. doi:10.1016/j.jacc.2013.11.059.
29.
TsirkaAETrinkausKChenSC, et al.Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. J Am Coll Cardiol. 2004;44(2):391-397. doi:10.1016/j.jacc.2004.04.035.
30.
MolinaKMShraderPColanSD, et al.Predictors of disease progression in pediatric dilated cardiomyopathy. Circ Heart Fail. 2013;6(6):1214-1222. doi:10.1161/CIRCHEARTFAILURE.113.000125.
31.
KantorPFAbrahamJRDipchandAIBensonLNRedingtonAN. The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol. 2010;55(13):1377-1384. doi:10.1016/j.jacc.2009.11.059.
MarstonNAHanLOlivottoI, et al.Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy. Eur Heart J. 2021;42(20):1988-1996. doi:10.1093/eurheartj/ehab148.
34.
MaronBJDoererJJHaasTSTierneyDMMuellerFO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980-2006. Circulation. 2009;119(8):1085-1092. doi:10.1161/CIRCULATIONAHA.108.804617.
MaronBJDesaiMYNishimuraRA, et al.Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79(4):372-389. doi:10.1016/j.jacc.2021.12.002.
37.
FinocchiaroGSheikhNBiaginiE, et al.The electrocardiogram in the diagnosis and management of patients with hypertrophic cardiomyopathy. Heart Rhythm. 2020;17(1):142-151. doi:10.1016/j.hrthm.2019.07.019.
38.
OmmenSRMitalSBurkeMA, et al.2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2020;76(25):3022-3055. doi:10.1016/j.jacc.2020.08.044.
39.
Lafreniere-RoulaMBolkierYZahavichL, et al.Family screening for hypertrophic cardiomyopathy: is it time to change practice guidelines?Eur Heart J. 2019;40(45):3672-3681. doi:10.1093/eurheartj/ehz396.
40.
MentiasARaeisi-GiglouPSmediraNG, et al.Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018;72(8):857-870. doi:10.1016/j.jacc.2018.05.060.
41.
TuohyCVKaulSSongHKNazerBHeitnerSB. Hypertrophic cardiomyopathy: the future of treatment. Eur J Heart Fail. 2020;22(2):228-240. doi:10.1002/ejhf.1715.
42.
JacobyDLesterSOwensA, et al.Reduction in left ventricular outflow tract gradient with mavacamten (MYK-461) in symptomatic obstructive hypertrophic cardiomyopathy patients (PIONEER-HCM). J Am Coll Cardiol. 2018;71(11):A644. doi:10.1016/S0735-1097(18)31185-9.
43.
CoppiniRFerrantiniCYaoL, et al.Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127(5):575-584. doi:10.1161/CIRCULATIONAHA.112.134932.
44.
OlivottoICamiciPGMerliniPA, et al.Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018;11(1): e004124. doi:10.1161/CIRCHEARTFAILURE.117.004124.
45.
MaronBJSpiritoPAckermanMJ, et al.Prevention of sudden cardiac death with implantable cardioverter - defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527-1535. doi:10.1016/j.jacc.2013.01.037.
46.
NorrishGChubbHFieldE, et al.Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK national cohort study. Europace. 2020;23(3):400-408. doi:10.1093/europace/euaa307.
47.
MaronBJDearaniJAOmmenSR, et al.The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;44(10):2044-2053. doi:10.1016/j.jacc.2004.04.063.
48.
TheodoroDADanielsonGKFeldtRHAndersonBJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: results of surgical treatment. J Thorac Cardiovasc Surg. 1996;112(6):1589-1597. doi:10.1016/S0022-5223(96)70018-1.
49.
BansalNBarachPAmdaniSMLipshultzSE. When is early septal myectomy in children with hypertrophic cardiomyopathy justified?Transl Pediatr. 2018;7(4):362-366. doi:10.21037/tp.2018.09.08.
50.
HolmesDRValetiUSNishimuraRA. Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Cathet Cardiovasc Interv. 2005;66(3):375-389. doi:10.1002/ccd.20500.
51.
VillaCBroderickJRizwanRLortsA. Utilization of VADs in children with restrictive and hypertrophic cardiomyopathy: are we there yet?Prog Pediatr Cardiol. 2018;49:47-49. doi:10.1016/j.ppedcard.2018.03.003.
52.
HoCYDaySMAshleyEA, et al.Genotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe). Circulation. 2018;138(14):1387-1398. doi:10.1161/CIRCULATIONAHA.117.033200.
53.
NorrishGTopriceanuCQuC, et al.The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy. Eur J Prev Cardiol. 2022;29(4):645-653. doi:10.1093/eurjpc/zwab046.
54.
MironALafreniere-RoulaMSteve FanCP, et al.A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142(3):217-229. doi:10.1161/CIRCULATIONAHA.120.047235.
55.
PaszkowskaAMirecka-RolaAPiekutowska-AbramczukD, et al.Spectrum of clinical features and genetic profile of left ventricular noncompaction cardiomyopathy in children. Cardiogenetics. 2021;11(4):191-203. doi:10.3390/cardiogenetics11040020.
56.
JefferiesJLWilkinsonJDSleeperLA, et al.Cardiomyopathy phenotypes and outcomes for children with left ventricular myocardial noncompaction: results from the pediatric cardiomyopathy registry. J Card Fail. 2015;21(11):877-884. doi:10.1016/j.cardfail.2015.06.381.
57.
PignatelliRHMcMahonCJDreyerWJ, et al.Clinical characterization of left ventricular noncompaction in children: a relatively common form of cardiomyopathy. Circulation. 2003;108(21):2672-2678. doi:10.1161/01.CIR.0000100664.10777.B8.
58.
MillerEMHintonRBCzosekR, et al.Genetic testing in pediatric left ventricular noncompaction. Circ Cardiovasc Genet. 2017;10(6):e001735. doi:10.1161/CIRCGENETICS.117.001735.
59.
CapturGNihoyannopoulosP. Left ventricular non-compaction: genetic heterogeneity, diagnosis and clinical course. Int J Cardiol2010;140(2):145-153. doi:10.1016/j.ijcard.2009.07.003.
60.
McMahonCJPignatelliRHNaguehSF, et al.Left ventricular non-compaction cardiomyopathy in children: characterisation of clinical status using tissue Doppler-derived indices of left ventricular diastolic relaxation. Heart. 2007;93(6):676-681. doi:10.1136/hrt.2006.093880.
61.
PetersenSESelvanayagamJBWiesmannF, et al.Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. J Am Coll Cardiol. 2005;46(1):101-105. doi:10.1016/j.jacc.2005.03.045.
62.
BresciaSTRossanoJWPignatelliR, et al.Mortality and sudden death in pediatric left ventricular noncompaction in a tertiary referral center. Circulation. 2013;127(22):2202-2208. doi:10.1161/CIRCULATIONAHA.113.002511.
ZuckermanWARichmondMESinghRKCarrollSJStarcTJAddonizioLJ. Left-ventricular noncompaction in a pediatric population: predictors of survival. Pediatr Cardiol. 2011;32(4):406-412. doi:10.1007/s00246-010-9868-5.
65.
Al-KindiSGEl-AmmCGinwallaMHoitBDParkSJOliveiraGH. Heart transplant outcomes in patients with left ventricular non-compaction cardiomyopathy. J Heart Lung Transplant. 2015;34(6):761-765. doi:10.1016/j.healun.2014.11.005.
66.
PunnRSilvermanNH. Cardiac segmental analysis in left ventricular noncompaction: experience in a pediatric population. J Am Soc Echocardiogr. 2010;23(1):46-53. doi:10.1016/j.echo.2009.09.003.
67.
MalčićIJelušićMKniewaldHBarišićNJelašićDBožikovJ. Epidemiology of cardiomyopathies in children and adolescents: a retrospective study over the last 10 years. Cardiol Young. 2002;12(3):253-259. doi:10.1017/S1047951102000550.
68.
WebberSALipshultzSESleeperLA, et al.Outcomes of restrictive cardiomyopathy in childhood and the influence of phenotype: a report from the pediatric cardiomyopathy registry. Circulation. 2012;126(10):1237-1244. doi:10.1161/CIRCULATIONAHA.112.104638.
RapezziCAimoABarisonA, et al.Restrictive cardiomyopathy: definition and diagnosis. Eur Heart J. 2022;43(45):4679-4693. doi:10.1093/eurheartj/ehac543.
71.
KaskiJPSyrrisPBurchM, et al.Idiopathic restrictive cardiomyopathy in children is caused by mutations in cardiac sarcomere protein genes. Heart. 2008;94(11):1478-1484. doi:10.1136/hrt.2007.134684.
72.
RussoLMWebberSA. Idiopathic restrictive cardiomyopathy in children. Heart. 2005;91(9):1199-1202. doi:10.1136/hrt.2004.043869.
73.
WellerRJWeintraubRAddonizioLJChrisantMRKGersonyWMHsuDT. Outcome of idiopathic restrictive cardiomyopathy in children. Am J Cardiol. 2002;90:501-506.
74.
RivenesSMKearneyDLSmithEOTowbinJADenfieldSW. Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation. 2000;102(8):876-882. https://www.circulationaha.org
75.
DitarantoRCaponettiAGFerraraV, et al.Pediatric restrictive cardiomyopathies. Front Pediatr. 2021;9:745365. doi:10.3389/fped.2021.745365.
76.
ChenSCBalfourICJureidiniS. Clinical spectrum of restrictive cardiomyopathy in children. J Heart Lung Transplant. 2001;20(1):90-92.
77.
TowbinJA. Cardiomyopathy and heart transplantation in children. Curr Opin Cardiol. 2002;17(3):274-279. doi:10.1097/00001573-200205000-00011.
78.
WittekindSGRyanTDGaoZ, et al.Contemporary outcomes of pediatric restrictive cardiomyopathy: a single-center experience. Pediatr Cardiol. 2019;40(4):694-704. doi:10.1007/s00246-018-2043-0.
79.
AndersonHNCettaFDriscollDJOlsonTMAckermanMJJohnsonJN. Idiopathic restrictive cardiomyopathy in children and young adults. Am J Cardiol. 2018;121(10):1266-1270. doi:10.1016/j.amjcard.2018.01.045.
80.
KimberlingMTBalzerDTHirschRMendeloffEHuddlestonCBCanterCE. Cardiac transplantation for pediatric restrictive cardiomyopathy: presentation, evaluation, and short-term outcome. J Heart Lung Transplant. 2002;21(4):455-459.
81.
CettaFO’learyPWSewardJBDriscollDJ. Idiopathic restrictive cardiomyopathy in childhood: diagnostic features and clinical course. Mayo Clin Proc. 1995;70:634-640.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
